JP2012506871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506871A5 JP2012506871A5 JP2011533398A JP2011533398A JP2012506871A5 JP 2012506871 A5 JP2012506871 A5 JP 2012506871A5 JP 2011533398 A JP2011533398 A JP 2011533398A JP 2011533398 A JP2011533398 A JP 2011533398A JP 2012506871 A5 JP2012506871 A5 JP 2012506871A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- carbamoyl
- acyl
- organism
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 229930186147 Cephalosporin Natural products 0.000 claims 3
- 229930182555 Penicillin Natural products 0.000 claims 3
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 3
- 108010059993 Vancomycin Proteins 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229940124587 cephalosporin Drugs 0.000 claims 3
- 150000001780 cephalosporins Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229960003276 erythromycin Drugs 0.000 claims 3
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 3
- 229960003165 vancomycin Drugs 0.000 claims 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 229910021386 carbon form Inorganic materials 0.000 claims 2
- 229940041033 macrolides Drugs 0.000 claims 2
- 150000002960 penicillins Chemical class 0.000 claims 2
- 150000007660 quinolones Chemical class 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 241000589242 Legionella pneumophila Species 0.000 claims 1
- 241000204031 Mycoplasma Species 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 102000002278 Ribosomal Proteins Human genes 0.000 claims 1
- 108010000605 Ribosomal Proteins Proteins 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 241001221452 Staphylococcus faecalis Species 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 241000193996 Streptococcus pyogenes Species 0.000 claims 1
- 241000202898 Ureaplasma Species 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002016 disaccharides Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 229940115932 legionella pneumophila Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10816808P | 2008-10-24 | 2008-10-24 | |
| US10811208P | 2008-10-24 | 2008-10-24 | |
| US10811008P | 2008-10-24 | 2008-10-24 | |
| US10813708P | 2008-10-24 | 2008-10-24 | |
| US10813408P | 2008-10-24 | 2008-10-24 | |
| US61/108,134 | 2008-10-24 | ||
| US61/108,110 | 2008-10-24 | ||
| US61/108,112 | 2008-10-24 | ||
| US61/108,168 | 2008-10-24 | ||
| US61/108,137 | 2008-10-24 | ||
| US16210909P | 2009-03-20 | 2009-03-20 | |
| US61/162,109 | 2009-03-20 | ||
| PCT/US2009/061977 WO2010048600A1 (en) | 2008-10-24 | 2009-10-24 | Methods for treating resistant diseases using triazole containing macrolides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014237428A Division JP5922210B2 (ja) | 2008-10-24 | 2014-11-25 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506871A JP2012506871A (ja) | 2012-03-22 |
| JP2012506871A5 true JP2012506871A5 (enExample) | 2012-12-06 |
| JP5715569B2 JP5715569B2 (ja) | 2015-05-07 |
Family
ID=42119711
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533398A Active JP5715569B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2011533397A Expired - Fee Related JP5711135B2 (ja) | 2008-10-24 | 2009-10-24 | 胃腸疾患を治療するための方法 |
| JP2011533399A Expired - Fee Related JP5602748B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2014167991A Expired - Fee Related JP6002185B2 (ja) | 2008-10-24 | 2014-08-20 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2014237428A Active JP5922210B2 (ja) | 2008-10-24 | 2014-11-25 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2014237346A Active JP5908569B2 (ja) | 2008-10-24 | 2014-11-25 | 胃腸疾患を治療するための方法 |
| JP2016080557A Active JP6309995B2 (ja) | 2008-10-24 | 2016-04-13 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2018047869A Pending JP2018115177A (ja) | 2008-10-24 | 2018-03-15 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2019189322A Pending JP2020023544A (ja) | 2008-10-24 | 2019-10-16 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2021146793A Active JP7171860B2 (ja) | 2008-10-24 | 2021-09-09 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533397A Expired - Fee Related JP5711135B2 (ja) | 2008-10-24 | 2009-10-24 | 胃腸疾患を治療するための方法 |
| JP2011533399A Expired - Fee Related JP5602748B2 (ja) | 2008-10-24 | 2009-10-24 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2014167991A Expired - Fee Related JP6002185B2 (ja) | 2008-10-24 | 2014-08-20 | トリアゾール含有マクロライドを用いた生体防御 |
| JP2014237428A Active JP5922210B2 (ja) | 2008-10-24 | 2014-11-25 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2014237346A Active JP5908569B2 (ja) | 2008-10-24 | 2014-11-25 | 胃腸疾患を治療するための方法 |
| JP2016080557A Active JP6309995B2 (ja) | 2008-10-24 | 2016-04-13 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2018047869A Pending JP2018115177A (ja) | 2008-10-24 | 2018-03-15 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2019189322A Pending JP2020023544A (ja) | 2008-10-24 | 2019-10-16 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
| JP2021146793A Active JP7171860B2 (ja) | 2008-10-24 | 2021-09-09 | トリアゾール含有マクロライドを用いた耐性疾患の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US9072759B2 (enExample) |
| EP (4) | EP2365747B1 (enExample) |
| JP (10) | JP5715569B2 (enExample) |
| CN (4) | CN107854477A (enExample) |
| AU (4) | AU2009308182B2 (enExample) |
| DK (1) | DK2358379T3 (enExample) |
| ES (3) | ES2676168T3 (enExample) |
| HK (1) | HK1252140A1 (enExample) |
| HR (1) | HRP20160222T1 (enExample) |
| SI (1) | SI2358379T1 (enExample) |
| WO (3) | WO2010048599A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2801100A1 (en) | 2003-03-10 | 2004-09-23 | Optimer Pharmaceuticals, Inc. | Macrolides and processes for their preparation |
| WO2009055557A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| EP2365747B1 (en) | 2008-10-24 | 2018-04-11 | Cempra Pharmaceuticals, Inc. | Methods for treating gastrointestinal diseases |
| US9937194B1 (en) | 2009-06-12 | 2018-04-10 | Cempra Pharmaceuticals, Inc. | Compounds and methods for treating inflammatory diseases |
| WO2011032052A1 (en) | 2009-09-10 | 2011-03-17 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and mac diseases |
| KR20180101643A (ko) * | 2010-03-22 | 2018-09-12 | 셈프라 파마슈티컬스, 인크. | 매크로라이드의 결정 형태들 및 그 용도들 |
| CN105198944B (zh) | 2010-05-20 | 2018-06-01 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| US9815863B2 (en) | 2010-09-10 | 2017-11-14 | Cempra Pharmaceuticals, Inc. | Hydrogen bond forming fluoro ketolides for treating diseases |
| JP6208742B2 (ja) | 2012-03-27 | 2017-10-04 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライド抗生物質を投与するための非経口製剤 |
| AU2014239959A1 (en) | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| KR20160020403A (ko) | 2013-03-15 | 2016-02-23 | 셈프라 파마슈티컬스, 인크. | 매크로라이드 항세균제들을 제조하기 위한 수렴 프로세스들 |
| KR102528984B1 (ko) * | 2013-04-04 | 2023-05-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 매크롤라이드 그리고 그의 제조방법 및 용도 |
| CN104151382B (zh) * | 2014-08-08 | 2016-09-14 | 广东东阳光药业有限公司 | 一种固态大环内酯的晶型 |
| CN104311611B (zh) * | 2014-08-13 | 2017-01-18 | 广东东阳光药业有限公司 | 一种制备固态大环内酯的方法 |
| JP2017531663A (ja) | 2014-10-08 | 2017-10-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | １４員ケトライドならびにそれらの調製および使用の方法 |
| HK1250371A1 (zh) | 2015-03-25 | 2018-12-14 | President And Fellows Of Harvard College | 具有修饰的脱氧糖胺糖的大环内酯及其用途 |
| CN106554992A (zh) * | 2015-09-28 | 2017-04-05 | 中国疾病预防控制中心传染病预防控制所 | 检测耐红霉素弯曲菌的试剂盒 |
| EP3582615A1 (en) * | 2017-02-17 | 2019-12-25 | Cempra Pharmaceuticals, Inc. | Triazole-containing macrolides and ophthalmic uses therefor |
| US10706191B2 (en) * | 2017-08-31 | 2020-07-07 | Google Llc | Systems and methods for generating a geo-level hierarchical Bayesian model |
| US11145299B2 (en) | 2018-04-19 | 2021-10-12 | X Development Llc | Managing voice interface devices |
Family Cites Families (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1354753A (en) | 1919-02-11 | 1920-10-05 | E M Lannes | Portable building |
| US2180006A (en) | 1936-09-09 | 1939-11-14 | Eastman Kodak Co | Process for the separation and refining of amines |
| GB891817A (en) | 1959-04-07 | 1962-03-21 | Upjohn Co | Improvements in or relating to injectable tetracyclic preparations |
| US3843787A (en) | 1969-01-15 | 1974-10-22 | Pierrel Spa | Water soluble derivative of erythromycin |
| US3668282A (en) | 1970-05-08 | 1972-06-06 | Stauffer Chemical Co | Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides |
| SE458505B (sv) | 1979-07-10 | 1989-04-10 | Lepetit Spa | Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning |
| US4331803A (en) * | 1980-06-04 | 1982-05-25 | Taisho Pharmaceutical Co., Ltd. | Novel erythromycin compounds |
| US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| JPS59175414A (ja) | 1983-03-23 | 1984-10-04 | Toyo Jozo Co Ltd | マクロライド抗生物質の安定な経口用製剤および安定化法 |
| US4742049A (en) | 1986-06-04 | 1988-05-03 | Abbott Laboratories | Semisynthetic erythromycin antibiotics |
| KR960000434B1 (ko) | 1986-12-17 | 1996-01-06 | 다이쇼 세이야꾸 가부시끼가이샤 | 에리스로마이신 a유도체 및 그의 제조 방법 |
| EP0283055B1 (en) | 1987-09-03 | 1990-08-29 | SOUR PLIVA farmaceutska, Kemijska prehrambena i kozmeticka industrija, n.sol.o. | 10-dihydro-10-deoxo-11-azaerythronolide-a-compounds, methods and intermediates for the manufacture thereof and their use in pharmaceuticals and in the manufacture thereof |
| BE1001869A3 (fr) | 1988-10-12 | 1990-04-03 | Franz Legros | Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine. |
| IL99995A (en) * | 1990-11-21 | 1997-11-20 | Roussel Uclaf | Erythromycin derivatives, their preparation and pharmaceutical compositions containing them |
| US5985844A (en) | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
| US5527780A (en) | 1992-11-05 | 1996-06-18 | Roussel Uclaf | Erythromycin derivatives |
| FR2697524B1 (fr) | 1992-11-05 | 1994-12-23 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2718450B1 (fr) * | 1994-04-08 | 1997-01-10 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| FR2719587B1 (fr) | 1994-05-03 | 1996-07-12 | Roussel Uclaf | Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments. |
| US5834428A (en) | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
| EP0863132B1 (en) * | 1995-06-28 | 2001-06-13 | Tokuyama Corporation | Ketonitrile derivatives and antibacterial agent and drug containing the same |
| FR2739620B1 (fr) | 1995-10-09 | 1997-12-19 | Roussel Uclaf | Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs |
| US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
| US5742049A (en) * | 1995-12-21 | 1998-04-21 | Bruker-Franzen Analytik Gmbh | Method of improving mass resolution in time-of-flight mass spectrometry |
| FR2742757B1 (fr) * | 1995-12-22 | 1998-01-30 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| FR2745290B1 (fr) | 1996-02-28 | 1998-04-03 | Roussel Uclaf | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| US5719272A (en) | 1996-04-02 | 1998-02-17 | Abbott Laboratories | 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives |
| PT1291350E (pt) * | 1996-09-04 | 2005-09-30 | Abbott Lab | Cetolidos 6-o-substituidos que possuem actividade antibacteriana |
| WO1998025895A1 (en) | 1996-12-13 | 1998-06-18 | Eli Lilly And Company | Inhibitors of the enzymatic activity of psa |
| HN1998000074A (es) | 1997-06-11 | 1999-01-08 | Pfizer Prod Inc | Derivados de macrolidos c-4 sustituidos |
| US6407074B1 (en) * | 1997-06-11 | 2002-06-18 | Pfizer Inc | C-4″-substituted macrolide derivatives |
| JP2000513026A (ja) | 1997-06-11 | 2000-10-03 | ファイザー・プロダクツ・インク | ９−オキシム エリスロマイシン誘導体 |
| HN1998000086A (es) | 1997-06-11 | 1999-03-08 | Pfizer Prod Inc | Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos. |
| HN1998000159A (es) | 1997-10-29 | 1999-02-09 | Monsanto Co | Derivados de 9- amino - 3 ceto eritromicina |
| IL135792A0 (en) | 1997-12-01 | 2001-05-20 | Abbott Lab | 6-o-alkyl derivatives of erythronolide b |
| US6440458B1 (en) * | 1998-03-26 | 2002-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparations |
| FR2777282B1 (fr) * | 1998-04-08 | 2001-04-20 | Hoechst Marion Roussel Inc | Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments |
| US6387885B1 (en) | 1998-08-26 | 2002-05-14 | Abbott Laboratories | 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists |
| US6020521A (en) * | 1998-08-26 | 2000-02-01 | Abbott Laboratories | Macrolide LHRH antagonists |
| FR2785612A1 (fr) | 1998-11-10 | 2000-05-12 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| FR2786188B1 (fr) * | 1998-11-24 | 2002-10-31 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments |
| KR100317907B1 (ko) | 1998-11-24 | 2001-12-24 | 김 완 주 | 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법 |
| EP1137654A1 (en) * | 1998-12-10 | 2001-10-04 | Pfizer Products Inc. | Carbamate and carbazate ketolide antibiotics |
| EE200100394A (et) | 1999-01-27 | 2002-10-15 | Pfizer Products Inc. | Ketoliidsed antibiootikumid |
| CA2292359C (en) | 1999-01-28 | 2004-09-28 | Pfizer Products Inc. | Novel azalides and methods of making same |
| FR2789392B1 (fr) | 1999-02-04 | 2001-10-05 | Hoechst Marion Roussel Inc | Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments |
| JP2000351794A (ja) | 1999-04-08 | 2000-12-19 | Hokuriku Seiyaku Co Ltd | エリスロマイシン誘導体 |
| AR023264A1 (es) | 1999-04-08 | 2002-09-04 | Hokuriku Pharmaceutical | Derivados de eritromicina |
| EP1171447A2 (en) | 1999-04-16 | 2002-01-16 | Ortho-McNeil Pharmaceutical, Inc. | Ketolide antibacterials |
| AU773678B2 (en) | 1999-04-16 | 2004-06-03 | Kosan Biosciences, Inc. | Macrolide antiinfective agents |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6420535B1 (en) * | 1999-06-07 | 2002-07-16 | Abbott Laboratories | 6-O-carbamate ketolide derivatives |
| US6437106B1 (en) * | 1999-06-24 | 2002-08-20 | Abbott Laboratories | Process for preparing 6-o-substituted erythromycin derivatives |
| AU6183700A (en) | 1999-08-06 | 2001-03-05 | Taisho Pharmaceutical Co., Ltd. | Erythromycin a derivatives |
| AU3337900A (en) | 1999-08-09 | 2001-03-05 | Eric Au | An apparatus for treating wastewater |
| US6096922A (en) | 1999-11-01 | 2000-08-01 | Air Products And Chemicals, Inc. | Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides |
| KR100336447B1 (ko) * | 1999-11-24 | 2002-05-15 | 민경윤 | 클라리스로마이신의 개선된 제조방법 |
| JP2001261694A (ja) * | 2000-03-06 | 2001-09-26 | Pfizer Prod Inc | ケトライド抗生物質 |
| MXPA02008861A (es) | 2000-03-15 | 2003-02-10 | Hanmi Pharm Ind Co Ltd | Metodo para preparar claritromicina de cristales de forma ii. |
| NZ523693A (en) | 2000-07-10 | 2004-08-27 | Chiron Corp | Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| US20020115621A1 (en) * | 2000-08-07 | 2002-08-22 | Wei-Gu Su | Macrolide antibiotics |
| GB0031312D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Macrolides |
| DE60210402T2 (de) | 2001-05-18 | 2006-12-07 | Chiron Corp., Emeryville | System zur Abgabe einer Tobramycin-Formulierung |
| US6756359B2 (en) | 2001-07-03 | 2004-06-29 | Chiron Corporation | C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| US20030176327A1 (en) * | 2001-10-25 | 2003-09-18 | Cassell Gail Houston | Antibiotics for treating biohazardous bacterial agents |
| AR038576A1 (es) | 2002-02-22 | 2005-01-19 | Pharmacia Corp | Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio |
| JP4638225B2 (ja) * | 2002-05-30 | 2011-02-23 | ザ スクリプス リサーチ インスティテュート | 銅を触媒とするアジドとアセチレンのライゲーション |
| BR0311885A (pt) | 2002-06-17 | 2005-04-05 | Epigenesis Pharmaceuticals Llc | Composição farmacêutica em pó, kit, e, métodos para a profilaxia ou tratamento da asma, para a profilaxia ou tratamento de doença pulmonar obstrutiva crÈnica, para reduzir ou exaurir a adenosina no tecido de um paciente, e para a profilaxia ou tratamento de um distúrbio ou condição associados com altos nìveis ou sensibilidade à adenosina no tecido de um paciente |
| JP4790263B2 (ja) | 2002-07-08 | 2011-10-12 | グラクソ グループ リミテッド | 炎症性の疾患および病態を治療する新規な化合物、組成物および方法 |
| US7091196B2 (en) | 2002-09-26 | 2006-08-15 | Rib-X Pharmaceuticals, Inc. | Bifunctional heterocyclic compounds and methods of making and using same |
| ITMI20022292A1 (it) * | 2002-10-29 | 2004-04-30 | Zambon Spa | 9a-azalidi ad attivita' antiinfiammatoria. |
| CA2801100A1 (en) | 2003-03-10 | 2004-09-23 | Optimer Pharmaceuticals, Inc. | Macrolides and processes for their preparation |
| WO2004096823A2 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Novel ketolide derivatives |
| US7332476B2 (en) | 2003-04-25 | 2008-02-19 | Novartis Ag | Pyridyl substituted ketolide antibiotics |
| ES2278319T3 (es) | 2003-05-13 | 2007-08-01 | Glaxo Group Limited | Nuevos compuestos con 14 y 15 miembros en el anillo. |
| US20050014706A1 (en) | 2003-07-14 | 2005-01-20 | Kanakeshwari Falzari | Method of treating tuberculosis |
| US7457520B2 (en) * | 2003-07-24 | 2008-11-25 | Time Warner Cable, Inc. | Technique for providing a virtual digital video recorder service through a communications network |
| GB0402578D0 (en) | 2004-02-05 | 2004-03-10 | Cambridge Theranostics Ltd | Methods of treatment of atherosclerosis |
| US20060116336A1 (en) | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| EP1742957B1 (en) | 2004-04-28 | 2007-09-12 | Alembic Limited | Process for the preparation of telithromycin |
| AU2005240849B2 (en) | 2004-05-06 | 2008-10-23 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Ester linked macrolides useful for the treatment of microbial infections |
| US20080287376A1 (en) * | 2004-07-28 | 2008-11-20 | Mohammad Salman | Ketolide Derivatives as Antibacterial Agents |
| GB0424958D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| GB0424959D0 (en) | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| WO2006075256A2 (en) * | 2005-01-14 | 2006-07-20 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity |
| WO2006106440A1 (en) | 2005-01-14 | 2006-10-12 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Macrolide compounds containing biotin and photo-affinity group for macrolide target identification |
| EP1841437B1 (en) | 2005-01-14 | 2009-04-29 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | 9a-carbamoyl and thiocarbamoyl azalides with antimalarial activity |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| JP2009500356A (ja) | 2005-07-07 | 2009-01-08 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クラリスロマイシン製剤 |
| US8048874B2 (en) | 2005-07-19 | 2011-11-01 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| CA2627740C (en) | 2005-10-31 | 2012-09-11 | Leo Pharma A/S | Preparation of a crystalline antibiotic substance |
| GB0522715D0 (en) | 2005-11-08 | 2005-12-14 | Helperby Therapeutics Ltd | New use |
| WO2007059307A2 (en) | 2005-11-15 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Crystalline and amorphous forms of telithromycin |
| EP1957508A2 (en) * | 2005-11-23 | 2008-08-20 | Ranbaxy Laboratories Limited | Ketolide derivatives as antibacterial agents |
| EP1954294A2 (en) | 2005-11-23 | 2008-08-13 | Ranbaxy Laboratories Limited | Use of macrolide derivatives for treating acne |
| DOP2006000268A (es) * | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
| CN101045063B (zh) | 2006-03-28 | 2011-01-26 | 广州朗圣药业有限公司 | 注射用克拉霉素水溶性制剂 |
| JP5126685B2 (ja) | 2006-05-01 | 2013-01-23 | 大正製薬株式会社 | マクロライド誘導体 |
| CA2654450A1 (en) | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
| DE102006036199B4 (de) * | 2006-08-03 | 2016-01-07 | Deere & Company | Förderzusammenbau und Presse |
| CN101129383B (zh) | 2006-08-25 | 2014-04-02 | 天津和美生物技术有限公司 | 含氨基糖苷类抗生素的抗生素复方 |
| WO2009055557A1 (en) | 2007-10-25 | 2009-04-30 | Cempra Pharmaceuticals, Inc. | Process for the preparation of macrolide antibacterial agents |
| US20090209547A1 (en) * | 2008-02-15 | 2009-08-20 | In Jong Kim | C-8 halogenated macrolides |
| EP2365747B1 (en) | 2008-10-24 | 2018-04-11 | Cempra Pharmaceuticals, Inc. | Methods for treating gastrointestinal diseases |
| US9814657B2 (en) | 2009-04-27 | 2017-11-14 | Premier Dental Products Company | Buffered microencapsulated compositions and methods |
| WO2011008193A1 (en) | 2009-07-13 | 2011-01-20 | Cempra Pharmaceuticals Inc. | Fusidic acid dosing regimens for treatment of bacterial infections |
| WO2011032052A1 (en) | 2009-09-10 | 2011-03-17 | Cempra Pharmaceuticals, Inc. | Methods for treating malaria, tuberculosis and mac diseases |
| US20110119604A1 (en) | 2009-11-19 | 2011-05-19 | Clevest Solutions Inc. | System and method for a configurable and extensible allocation and scheduling tool |
| JP5890785B2 (ja) | 2010-03-10 | 2016-03-22 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライド抗生物質の非経口製剤 |
| KR20180101643A (ko) | 2010-03-22 | 2018-09-12 | 셈프라 파마슈티컬스, 인크. | 매크로라이드의 결정 형태들 및 그 용도들 |
| CN105198944B (zh) | 2010-05-20 | 2018-06-01 | 森普拉制药公司 | 制备大环内酯和酮内酯及其中间体的方法 |
| US8247394B2 (en) | 2010-06-02 | 2012-08-21 | Cempra Pharmaceuticals Inc. | Methods of treating urethritis and related infections using fusidic acid |
| US9260473B2 (en) | 2010-07-19 | 2016-02-16 | Virginia Commonwealth University | Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease |
| CA2812044A1 (en) | 2010-08-30 | 2012-03-08 | Cempra Pharmaceuticals Inc. | Methods of treating bacterial infections through pulmonary delivery of fusidic acid |
| US9815863B2 (en) | 2010-09-10 | 2017-11-14 | Cempra Pharmaceuticals, Inc. | Hydrogen bond forming fluoro ketolides for treating diseases |
| WO2012042534A2 (en) | 2010-09-28 | 2012-04-05 | Glenmark Generics Limited | Processes for the preparation of r-sitagliptin and intermediates thereof |
| US20140088062A1 (en) | 2011-05-23 | 2014-03-27 | Cem-102 Pharmaceuticals, Inc. | Compositions comprising fusidic acid and packages therefor |
| PT2748165T (pt) | 2011-08-27 | 2016-12-28 | Wockhardt Ltd | Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas |
| HK1199725A1 (en) | 2011-08-29 | 2015-07-17 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| WO2013059610A1 (en) | 2011-10-20 | 2013-04-25 | Trius Therapeutics, Inc. | Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use |
| JP6208742B2 (ja) | 2012-03-27 | 2017-10-04 | センプラ ファーマシューティカルズ，インコーポレイテッド | マクロライド抗生物質を投与するための非経口製剤 |
| AU2014239959A1 (en) | 2013-03-14 | 2015-10-01 | Cempra Pharmaceuticals, Inc. | Methods for treating respiratory diseases and formulations therefor |
| KR20160020403A (ko) | 2013-03-15 | 2016-02-23 | 셈프라 파마슈티컬스, 인크. | 매크로라이드 항세균제들을 제조하기 위한 수렴 프로세스들 |
| KR102528984B1 (ko) | 2013-04-04 | 2023-05-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 매크롤라이드 그리고 그의 제조방법 및 용도 |
| AU2015217293A1 (en) | 2014-02-14 | 2016-09-01 | Cempra Pharmaceuticals, Inc. | Compositions and methods for treating diabetes and liver diseases |
| WO2015181723A1 (en) | 2014-05-27 | 2015-12-03 | Dipharma Francis S.R.L. | Azidoalkylamine salts and their use as intermediates |
| SG11201700827RA (en) | 2014-08-05 | 2017-03-30 | Cempra Pharmaceuticals Inc | Powder oral suspension formulations of antibacterial agents |
| BR112017019176A2 (pt) | 2015-03-06 | 2018-04-24 | Cempra Pharmaceuticals Inc | processos para a preparação de fluorocetolídeos |
-
2009
- 2009-10-24 EP EP09822826.5A patent/EP2365747B1/en not_active Not-in-force
- 2009-10-24 JP JP2011533398A patent/JP5715569B2/ja active Active
- 2009-10-24 CN CN201711145739.1A patent/CN107854477A/zh active Pending
- 2009-10-24 ES ES09822826.5T patent/ES2676168T3/es active Active
- 2009-10-24 ES ES09822828.1T patent/ES2565083T3/es active Active
- 2009-10-24 DK DK09822828.1T patent/DK2358379T3/en active
- 2009-10-24 EP EP09822828.1A patent/EP2358379B1/en not_active Not-in-force
- 2009-10-24 CN CN201610045028.6A patent/CN105616437A/zh active Pending
- 2009-10-24 US US13/125,550 patent/US9072759B2/en not_active Expired - Fee Related
- 2009-10-24 WO PCT/US2009/061976 patent/WO2010048599A1/en not_active Ceased
- 2009-10-24 AU AU2009308182A patent/AU2009308182B2/en not_active Ceased
- 2009-10-24 JP JP2011533397A patent/JP5711135B2/ja not_active Expired - Fee Related
- 2009-10-24 JP JP2011533399A patent/JP5602748B2/ja not_active Expired - Fee Related
- 2009-10-24 ES ES09822827.3T patent/ES2677007T3/es active Active
- 2009-10-24 US US13/125,551 patent/US8791080B2/en not_active Expired - Fee Related
- 2009-10-24 AU AU2009308180A patent/AU2009308180B2/en not_active Ceased
- 2009-10-24 WO PCT/US2009/061978 patent/WO2010048601A1/en not_active Ceased
- 2009-10-24 US US13/125,555 patent/US8796232B2/en not_active Expired - Fee Related
- 2009-10-24 CN CN200980150068.5A patent/CN102245195B/zh not_active Expired - Fee Related
- 2009-10-24 EP EP15186676.1A patent/EP3031460A1/en not_active Withdrawn
- 2009-10-24 EP EP09822827.3A patent/EP2362727B1/en not_active Not-in-force
- 2009-10-24 SI SI200931385A patent/SI2358379T1/sl unknown
- 2009-10-24 CN CN200980146721.0A patent/CN102223794B/zh not_active Expired - Fee Related
- 2009-10-24 HR HRP20160222TT patent/HRP20160222T1/hr unknown
- 2009-10-24 AU AU2009308181A patent/AU2009308181B2/en not_active Ceased
- 2009-10-24 WO PCT/US2009/061977 patent/WO2010048600A1/en not_active Ceased
-
2014
- 2014-06-19 US US14/309,202 patent/US9901592B2/en not_active Expired - Fee Related
- 2014-06-19 US US14/309,178 patent/US9439918B2/en not_active Expired - Fee Related
- 2014-08-20 JP JP2014167991A patent/JP6002185B2/ja not_active Expired - Fee Related
- 2014-11-25 JP JP2014237428A patent/JP5922210B2/ja active Active
- 2014-11-25 JP JP2014237346A patent/JP5908569B2/ja active Active
-
2015
- 2015-05-29 US US14/725,247 patent/US9669046B2/en not_active Expired - Fee Related
-
2016
- 2016-04-13 JP JP2016080557A patent/JP6309995B2/ja active Active
- 2016-04-28 AU AU2016202707A patent/AU2016202707A1/en not_active Abandoned
-
2018
- 2018-01-19 US US15/875,187 patent/US20180369262A1/en not_active Abandoned
- 2018-03-15 JP JP2018047869A patent/JP2018115177A/ja active Pending
- 2018-09-07 HK HK18111531.3A patent/HK1252140A1/zh unknown
-
2019
- 2019-10-16 JP JP2019189322A patent/JP2020023544A/ja active Pending
-
2021
- 2021-09-09 JP JP2021146793A patent/JP7171860B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012506871A5 (enExample) | ||
| JP2015078203A5 (enExample) | ||
| JP2012506870A5 (enExample) | ||
| JP2011530534A5 (enExample) | ||
| JP2012513467A5 (enExample) | ||
| HRP20130928T1 (hr) | C7-fluor supstituirani spojevi tetraciklina | |
| JP2012506872A5 (enExample) | ||
| JP2013523761A5 (enExample) | ||
| DK1506214T3 (da) | 6-11 bicykliske ketolidderivater | |
| CL2013002313A1 (es) | Compuestos macrólidos derivados de eritromicina sustituidos en posición c-4” con metil amino sustituido con actividad antibiótica; compuestos intermediarios; composición farmacéutica, uso en profilaxis o tratamiento de infecciones bacterianas resistentes a la eritromicina. | |
| CA2286511C (en) | Novel macrolide derivatives | |
| HRP20131170T1 (hr) | Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija | |
| JP2009539970A5 (enExample) | ||
| RU2013137752A (ru) | Твердые формы ингибитора гиразы (r)-1-этил-3-[6-фтор-5[2-(1-гидрокси-1-метил-этил) пиримидин-5-ил]-7-(тетрагидрофуран-2-ил)-1н-бензимидазол-2-ил] мочевины | |
| HRP20191295T1 (hr) | Kristalne soli amida (4s,4as,5ar,12as)-4-dimetilamino-3,10,12,12a-tetrahidroksi-7-[(metoksi(metil)amino)-metil]-1,11-diokso-1,4,4a,5,5a,6,11,12a-oktahidro-naftacen-2-karboksilne kiseline i postupci uporabe istih | |
| JP2011528354A5 (enExample) | ||
| JP2011526887A5 (enExample) | ||
| JP2018523675A5 (enExample) | ||
| WO2009075923A3 (en) | 6, 11-bridged biaryl macrolides | |
| JP2010507576A5 (enExample) | ||
| Magee et al. | Novel 3-O-carbamoyl erythromycin A derivatives (carbamolides) with activity against resistant staphylococcal and streptococcal isolates | |
| Wang et al. | Synthesis and antibacterial activity of novel 4 ″-O-(1-aralkyl-1, 2, 3-triazol-4-methyl-carbamoyl) azithromycin analogs | |
| Liang et al. | Structure–activity relationships of novel alkylides: 3-O-Arylalkyl clarithromycin derivatives with improved antibacterial activities | |
| Xu et al. | Synthesis and antibacterial activity of C2-fluoro, C6-carbamate ketolides, and their C9-oximes | |
| JP2019534289A5 (enExample) |